Last updated 4 September 2020
We commit to ensuring the quality, safety and reliable supply of our products. If the supply of our medicines or vaccines is disrupted in Australia we will publish details here.
At this unprecedented time, we are actively managing our global supply chains to minimise potential disruption, and we are monitoring the situation closely. We will put the needs of patients first at all times.
At present, with the exception of specific supply disruptions as outlined below, we have adequate stock in place in Australia.
We support the Government and Pharmacy industry's steps to introduce limits on dispensing and sales of prescription and over-the-counter medicines during the COVID-19 pandemic to ensure patients can access the medicines they need.
Flixotide (fluticasone propionate) 0.5 mg/2 mL nebules
Flixotide 0.5 mg/2 mL nebules are currently unavailable due to high global demand. Supply in Australia is expected to recommence in February 2021. Please consult your healthcare professional should you require an alternative.
Haemophilius influenzae type B (Hib) vaccine, HIBERIX
GSK is experiencing a supply constraint of our Haemophilius influenzae type B (Hib) vaccine, HIBERIX in the private market (Hiberix is not supplied on the National Immunisation Program). Healthcare professionals and patients may not be able to access HIBERIX vaccines temporarily until we return to supply. This supply constraint is caused by an unexpected increase in local demand in the first half of 2020. We expect to have an update available in December 2020.
- VENTOLIN INHALER CFC-Free Salbutamol 100 microgram (as sulfate) pressurised inhaler metered dose
- VENTOLIN INHALER CFC-Free Salbutamol 100 microgram (as sulfate) pressurised inhaler metered dose (with counter)
From August 2020, an updated Ventolin (salbutamol) inhaler with a dose counter will be introduced gradually over a period of four to six months, while existing stock of VENTOLIN (without dose counter) continues to be sold in pharmacies.
While Australians may see limited availability of VENTOLIN with dose counter in the early months, the full transition is expected to be complete by early 2021. After this time, all VENTOLIN inhalers available will have a dose counter.
The inhaler with dose counter operates the same way for patients and contains the same medication and same dose. The only change is the integration of a dose counter which will allow patients to view the number of doses remaining in their inhalers.
The transition to the Ventolin (salbutamol) inhaler with dose counter is not expected to impact supply, though we continue to closely monitor the continuing peaks in demand which have occurred in the first half of 2020.
We maintain good stock levels of Ventolin inhalers, however we will continue to monitor the situation to ensure supplies are distributed to where they are needed. Unprecedented and unpredictable high consumer demand for Ventolin (salbutamol) inhalers across Australia in the first half of 2020 may still periodically impact availability in some areas of the country at a pharmacy level.
Please visit the TGA website for ongoing updates to supply.
For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.